AGONIST-ANTAGONIST ACTIVITY OF ANTIESTROGENS IN THE HUMAN BREAST-CANCER CELL-LINE MCF-7 - AN HYPOTHESIS FOR THE INTERACTION WITH A SITE DISTINCT FROM THE ESTROGEN-BINDING SITE
Y. Berthois et al., AGONIST-ANTAGONIST ACTIVITY OF ANTIESTROGENS IN THE HUMAN BREAST-CANCER CELL-LINE MCF-7 - AN HYPOTHESIS FOR THE INTERACTION WITH A SITE DISTINCT FROM THE ESTROGEN-BINDING SITE, Molecular and cellular endocrinology, 99(2), 1994, pp. 259-268
Non-steroidal anti-estrogens exhibit an extremely complex pharmacology
because of their estrogenic and anti-estrogenic effects in different
species. Recently, we have reported evidence for an immunochemical dif
ference in the estrogen receptor (ER) when it is occupied with anti-es
trogens as compared to estrogens (Martin et al., 1988). In this study,
we have compared immunoreactivity of MCF-7 cell estrogen receptor whe
n bound to anti-estrogen versus estrogen. We show that the occupation
of ER with antiproliferative concentrations of various anti-estrogens
leads to the appearance of additional antigenic determinants for the H
222 monoclonal anti-estrogen receptor antibody. When performing ER imm
unoassay after sedimentation of estrogen receptors on sucrose gradient
s, we show that exposure of new epitopes induced by anti-estrogens can
occur on a 4 s molecular form related to the 66 kDa monomeric estroge
n receptor. Also, when ER are previously occupied by estradiol, the ad
dition of low anti-estrogen concentrations, which are unable to displa
ce estradiol from the estrogen receptor, leads to a significant increa
se of H222 epitopes. Our results led us to propose a molecular model f
or anti-estrogen-receptor interaction in which their dual agonist/anta
gonist activity may be due to the occupation of distinct binding sites
on the estrogen receptor.